Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Common Equity (2016 - 2025)

Historic Common Equity for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $87.8 million.

  • Coherus Oncology's Common Equity rose 19977.38% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 19977.38%. This contributed to the annual value of -$132.0 million for FY2024, which is 3176.17% up from last year.
  • Coherus Oncology's Common Equity amounted to $87.8 million in Q3 2025, which was up 19977.38% from $119.8 million recorded in Q2 2025.
  • Coherus Oncology's Common Equity's 5-year high stood at $156.2 million during Q2 2021, with a 5-year trough of -$196.5 million in Q1 2023.
  • In the last 5 years, Coherus Oncology's Common Equity had a median value of -$84.1 million in 2024 and averaged -$41.7 million.
  • Per our database at Business Quant, Coherus Oncology's Common Equity crashed by 166417.26% in 2023 and then soared by 24246.8% in 2025.
  • Coherus Oncology's Common Equity (Quarter) stood at $97.7 million in 2021, then crashed by 240.62% to -$137.4 million in 2022, then crashed by 40.76% to -$193.4 million in 2023, then surged by 31.76% to -$132.0 million in 2024, then surged by 166.5% to $87.8 million in 2025.
  • Its Common Equity was $87.8 million in Q3 2025, compared to $119.8 million in Q2 2025 and -$183.5 million in Q1 2025.